DIGI-INTERNATIONAL
21.6.2022 09:02:08 CEST | Business Wire | Press release
Digi International ® , (NASDAQ: DGII) - a leading global provider of Internet of Things (IoT) connectivity products, solutions, services and wireless data plans - today announced it will showcase a wide range of its new solutions and devices at Embedded World 2022 that enable medical, transportation, agriculture and industrial enterprises to create innovative solutions faster.
Digi’s first-look of its Digi ConnectCore MP1 system-on-modules, Digi ConnectCore Voice Control software, and Digi XBee Intelligent Edge Controller takes place at Bressner Technology booth 1-236 in Hall 1. Digi ConnectCore MP1 is also on display at STMicroelectronics Wall of SOMs booth 4A-148. There are live demos of Digi XBee and its IX15 gateway and the new Digi ConnectCore Voice Control application at the NXP booth 4A-222.
Bolstered by Digi Remote Manager® —the command center of an intelligent network—Digi’s new and smaller embedded IoT technologies dramatically improve the way people, machines and processes interact. Network connectivity is the fundamental key to the true potential of these technologies that place Digi at the forefront of some of the most advanced networking solutions combining software, hardware and services for enterprises.
“This is an exceptionally exciting year to return to Embedded World,” said Andreas Burghart, Senior Product Manager at Digi. “Advances in connectivity and IoT devices are spurring the rapid development of next-generation, cost-effective, integrated solutions. That’s unleashing new waves of innovation across numerous industries that require reliable and secure connectivity. We’re looking forward to sharing our progress and collaborating with our customers on breakthrough embedded solutions.”
Digi’s Embedded World 2022 solution showcase includes three new or recently launched products:
- Digi ConnectCore® MP1 Family – The Digi ConnectCore® MP1 family of system-on-modules (SOMs) features the industry’s smallest STM32MP1 SOM that integrates Wi-Fi, Bluetooth and wired connectivity without comprising design flexibility. The solution also features its Connected Device platform and well-tested development tools and design support. Digi ConnectCore MP1 SOMs offer a cost-effective wireless solution for OEMs seeking to reduce product-development risk and effort.
- Digi ConnectCore Voice Control Software – This advanced voice-control software solution is designed for the acclaimed ConnectCore family of system-on-modules (SOMs). Digi ConnectCore Voice Control is a fully integrated, ready-to use software solution that enables developers to design a voice-based human-machine interface (HMI) to control device operations using speech. It provides voice processing on edge devices (including support for 30 languages and a 60,000-word vocabulary) with no cloud connectivity required. That reduces connectivity costs and data-privacy concerns while providing response times of less than 100ms.
- Digi XBee® Intelligent Edge Controller (IEC) - The Digi XBee® Intelligent Edge Controller (IEC) delivers a comprehensive networking architecture to close the gap between field devices and the cloud and provide powerful asset monitoring and control. In combination with Digi X-ON cloud, the Digi XBee IEC helps companies monitor sensors or remote-control assets over long-range, low-power wide area networks, including LoRaWAN, CAT-M1, and NB-IoT. Industrial devices can be monitored with sub-second latency with alarms and data wirelessly delivered through the Digi X-ON cloud.
At Embedded World, Digi will also demonstrate its wireless IoT solution for smart agriculture with a simulation of a complete ecosystem that can centrally manage multiple farms. This end-to-end solution provides crop managers with real-time weather conditions that help determine optimal irrigation cycles, maximize crop yields and lower labor and supply costs. The heart of the system is the Digi IX15 gateway and cellular router that communicates with irrigation pumps through a wireless mesh network of Digi XBee® modules. Using Digi Remote Manager® and a cloud-based web application, a crop manager monitors exact weather and soil conditions at each farm, and controls individual pumps. The commands pass through the internet to the IX15 by a cellular network, and the IX15 relays the commands to the XBee modules at each pump, turning them on and off remotely.
Digi will also preview its upcoming Digi ConnectCore 93, which includes NXP’s i.MX 93 system-on-a-chip (SOC). Digi is one of six Early Access Partners for this April 2023 release.
For more information about Digi, stop by Bresser Technology Booth 1-236 in Hall 1 or visit: www.digi.com .
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005096/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom